LCLucia Carpineta

Lucia Carpineta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lucia Carpineta has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Pediatric temporal bone fractures: A case series

    by S. Waissbluth, R. Ywakim, B. Al Qassabi, B. Torabi, L. Carpineta, J. Manoukian, L.H.P. Nguyen


  • Appendicitis in adults with incidental midgut malrotation: CT findings

    by A. Ben Ely, N. Gorelik, Y. Cohen-Sivan, R. Zissin, L. Carpineta, A. Osadchy, G. Gayer


  • Cystic fibrosis presenting as bilateral maxillary mucoceles in an infant

    by Lana Wazqar, Alipasha Rassouli, Nader Emami Esfahani, Lucia Carpineta, Sam J. Daniel

  • Hepatobiliary Tumors

    by Ricardo Faingold, Pedro A.B. Albuquerque, Lucia Carpineta


  • Reply: Rituximab-induced pneumonitis: Steroid therapy or not?

    by Martin Bitzan, Mark Anselmo, Lucy Carpineta

  • Cryptogenic organizing pneumonia after rituximab therapy for presumed post-kidney transplant lymphoproliferative disease

    by Martin Bitzan, Jodie D. Ouahed, Lucy Carpineta, Chantal Bernard, Lorraine E. Bell

    Cryptogenic organizing pneumonia (COP, formerly bronchiolitis obliterans organizing pneumonia) is rare in children. We describe an 11-year-old girl with Epstein–Barr virus (EBV) reactivation/presumed post-transplant lymphoproliferative disease (PTLD) 15 months after undergoing a deceased donor kidney transplantation. Treatment with reduced immunosuppression, ganciclovir, and cytomegalovirus immunoglobulin was complicated by severe graft rejection, prompting therapy with methylprednisolone, anti-thymocyte globulin and four weekly doses of rituximab (total 1500 mg/m2). Tacrolimus- and prednisone-based anti-rejection prophylaxis was complemented with low-dose sirolimus. When the lactate dehydrogenase and uric acid levels rose 10 weeks after the first rituximab infusion and bilateral pulmonary nodules were detected by computerized tomography, recurrence of PTLD was suspected. Open lung biopsy of the clinically asymptomatic patient identified the nodules as COP, characterized by abundant CD3+ T-cells, few B-cells, and the absence of EBV, cytomegalovirus, or adenovirus antigens. With normalization of the peripheral B-cell count, EB viremia reappeared and persisted, despite minimal immunosuppression. Four years later, the patient was diagnosed with classical Hodgkin lymphoma-type PTLD with multiple pulmonary and abdominal nodes. This first report of rituximab-associated, pediatric COP highlights the risk of pulmonary complications after treatment with B-cell depleting agents in solid organ transplant recipients, and the importance of a histopathologic diagnosis and vigilant follow-up of such lesions.


  • Rituximab (B‐cell depleting antibody) associated lung injury (RALI): A pediatric case and systematic review of the literature

    by Martin Bitzan, Mark Anselmo, Lucy Carpineta

    Introduction: Pulmonary toxicity of delayed onset is a rare complication of B‐lymphocyte depleting antibody therapy and has been almost exclusively reported in older patients with B‐cell malignancies.Aims: To describe a pediatric patient with rituximab‐associated lung injury (RALI), to systematically analyze previous reports of pulmonary complications, and to summarize common clinico‐pathological features, treatment, and outcome.Results: A teenage boy with focal segmental glomerulosclerosis (FSGS) presented with progressive dyspnea, fever, hypoxemia and fatigue 18 days after the completion of a second course of rituximab infusions for calcineurin inhibitor‐dependent nephrotic syndrome. Respiratory symptoms started while he received high‐dose prednisone for persistent proteinuria. Bilateral, diffuse ground‐glass infiltrates corresponded to the presence of inflammatory cells in the bronchioalveolar lavage fluid. Empiric antibiotic treatment including clarithromycin was given, but the microbiological work‐up remained negative. Serum IgE, C3, and C4 concentrations were normal. He recovered within 3 weeks after onset.We systematically reviewed 23 reports describing 30 additional cases of rituximab‐associated lung disease. Twenty eight patients had received rituximab for B‐cell malignancies, one for graft‐versus‐host disease and one for immune thrombocytopenia. Median age was 64 years (interquartile range [IQR] 58–69 years). Seventy one percent received concomitant chemotherapy. Time to onset from the last rituximab dose was 14 days (IQR 11–22 days). Eleven of 31 patients required mechanical ventilation, and 9 died (29%). Ventilation was a significant predictor of fatal outcome (odds ratio 46.7; confidence interval 9.5–229.9). High dose glucocorticoid therapy did not improve survival or prevent severe lung disease or death.Conclusions: With the expanding use of rituximab for novel indications, additional cases of RALI affecting younger age groups are expected to emerge. Mechanical ventilation predicts poor outcome. Glucocorticoids may not be protective. Pediatr Pulmonol. 2009; 44:922–934.


  • Polypoid PEComa in the Rectum of a 15-year-old Girl

    by Paul Ryan, Van-Hung Nguyen, Suad Gholoum, Lucia Carpineta, Sharon Abish, Najma N. Ahmed, Jean-Martin Laberge, Robert H. Riddell

    PEComa of the gastrointestinal tract, composed of perivascular epithelioid cells with myomelanocytic differentiation, is rare with previous literature limited to 16 case reports. There is a marked female preponderance and approximately one-third of the cases occur in the pediatric age group. We report PEComa with lymph node involvement occurring in the rectum of a 15-year-old girl, treated by surgical resection and adjuvant chemotherapy. The patient is well at 9 months follow-up with neither radiologic nor endoscopic evidence of recurrence. We review the differential diagnosis of intestinal PEComa, which includes malignant melanoma, epithelioid gastrointestinal stromal tumors, clear cell sarcoma of soft parts, alveolar soft part sarcoma, leiomyosarcoma with HMB45 expression, and paraganglioma. Immunohistochemistry can rule out many of these morphologically similar tumors but differentiation from clear cell sarcoma may require reverse transcription-polymerase chain reaction. We discuss the determination of pathologic features indicative of malignancy in PEComa, which is complicated in the gastrointestinal tract due to the small number of cases, variability of pathologic features reported, and inconsistent reporting of outcome. All 4 tumors reporting early recurrence or progression were greater than 5 cm in size and had areas of coagulative tumor necrosis. In addition, high nuclear grade and lymphovascular invasion were seen in 2 of these 4 cases. We propose that a minimum dataset for gastrointestinal PEComa should include these features along with mitotic count, infiltrative border, and tumor stage analogous to that used in colorectal carcinoma.


  • Spinal Hamartoma with Severe Kyphoscoliosis – A Rare Case of Spinal Mass in a Fetus

    by Danna Loder, Maria Lalous, Louise Rochon, Steffen Albrecht, Lucia Carpineta, Josée Lefebvre, Jennifer Fitzpatrick, Louise Miner, Marc Tischkowitz

    Spinal hamartomas are rare lesions consisting of disorganized ecto- and mesodermal tissues of the spinal region. While postnatal identification of spinal hamartomas has been reported, a literature search did not reveal any published reports of prenatal identification of spinal hamartomas. Here we report a 46,XX fetus who presented at 20 weeks’ gestation with a lower thoracic and lumbar kyphoscoliosis, suspected spina bifida, and amniotic fluid α-fetoprotein (AFP) levels within the normal range. Interestingly, autopsy at 22 weeks revealed a lumbosacral spinal hamartoma with kyphoscoliosis. We discuss the differential diagnosis for such spinal masses which includes congenital tumors and spinal dysraphism. This case illustrates that spinal hamartomas should be considered as part of the prenatal differential diagnosis of spinal dysraphisms, especially in the presence of normal AFP levels.